Feature

NCI grant to fund study of CAR T-cell therapy for solid tumors

January 2, 2019
A $10.7 million grant from NCI will fund research at University of Pennsylvania’s Abramson Cancer Center to evaluate the use of chimeric…

FDA News

FDA issues new framework for oncology drug development

December 19, 2018
The FDA today issued new guidance to help drug developers select endpoints for marketing applications with the goal of advancing the efficient…

Meeting News

B-cell maturation antigen-targeted CAR T-cell therapy potent in advanced myeloma

December 17, 2018
SAN DIEGO — B-cell maturation antigen chimeric antigen receptor T cells that harbor a fully human single-chain variable fragment with a defined…

Meeting News

CAR T-cell therapy cost-effective compared with past treatments

December 14, 2018
SAN DIEGO — Chimeric antigen receptor T-cell therapy has improved health outcomes at a more cost-effective rate than other cancer treatments…

Clinical Trials Snapshot

Use of Ligand-Inducible Autologous T-cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors

Cell Therapy Next, December 2018
Phase 1/2 study looking to evaluate the safety and activity of BPX-601 in previously treated advanced solid tumors (gastric, pancreatic or prostate)…

Editorial

Welcome to the Premier Issue of Cell Therapy Next

Cell Therapy Next, December 2018
With the approval of two chimeric antigen receptor T-cell therapies in the past year, the need arose for quality information and education about…

Clinical Trials Snapshot

HER2-CAR T-cells in Treating Participants with Brain or Leptomeningeal Metastases

Cell Therapy Next, December 2018
Phase 1 trial looking at side effects and best dose of HER2-CAR T-cells in treating cancer that has metastasized to the brain or leptomeninges by…

Patient Selection: The Key First Step to Successful CAR T-cell Therapy

Cell Therapy Next, December 2018
In the In Practice column, Cell Therapy Next will work with members of the Peer Perspective Board to break down the practical knowledge needed to…

Cover Story

From Research to Manufacturing to Treatment: A One-Stop CAR T Shop

Cell Therapy Next, December 2018
When Carl H. June, MD, came to the University of Pennsylvania, his theory of manipulating chimeric antigen receptor T-cells remained in…

Clinical Trials Snapshot

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma

Cell Therapy Next, December 2018
Phase 1, open-label dose escalation study to determine the most effective and safest dose of GD2-CAR natural killer T-cells (NKT cells; GINAKIT…

Clinical Trials Snapshot

EGFR806 CAR T-cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Cell Therapy Next, December 2018
Phase I, open-label, non-randomized study enrolling pediatric and young adults with relapsed or refractory non-CNS solid tumors to evaluate safety…

Clinical Trials Snapshot

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

Cell Therapy Next, December 2018
Single center, single arm phase 1 study to establish the safety and feasibility of intravenously administered, lentivirally transduced, dual…

Clinical Trials Snapshot

A Phase I/II Study Administering Peripheral Blood Lymphocytes (PBL) Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70 Expressing Cancers

Cell Therapy Next, December 2018
Phase 1 study set to determine safety of administering PBL transduced with anti-hCD70 CAR in conjunction with lymphodepletion and high-dose…

Meeting NewsPerspective

Single tisagenlecleucel infusion yields durable response in acute lymphoblastic leukemia

December 2, 2018
SAN DIEGO — An updated analysis of the phase 2 ELIANA trial confirmed the efficacy of a single infusion of the chimeric antigen receptor T-cell…

Meeting News

Progressive disease after anti-CD19 CAR T-cell therapy predicts poor lymphoma survival

December 2, 2018
SAN DIEGO — Patients with large B-cell lymphoma who experienced progressive disease following anti-CD19 chimeric antigen receptor T-cell…

Meeting NewsPerspective

Ibrutinib plus CD19-specific CAR T-cell therapy may benefit patients with relapsed or refractory CLL

December 2, 2018
SAN DIEGO — Administration of ibrutinib beginning 2 weeks prior to leukapheresis and continuing until 3 months after CD19-specific chimeric…

Meeting NewsPerspective

Tisagenlecleucel induces durable response among adults with pretreated diffuse large B-cell lymphoma

December 1, 2018
SAN DIEGO — Chimeric antigen receptor T-cell therapy with tisagenlecleucel induced durable responses among heavily pretreated adults with…

Meeting NewsPerspective

Consolidative transplant after CAR T-cell therapy may benefit certain patients with acute lymphoblastic leukemia

December 1, 2018
SAN DIEGO — Consolidative hematopoietic stem cell transplant after CD19-directed chimeric antigen receptor T-cell therapy prolonged…

Feature

Trial to assess CAR T-cell therapy for certain lymphomas, leukemias

November 27, 2018
Researchers are launching a first-in-human clinical trial to assess the use of chimeric antigen receptor T-cell therapy targeting the CD4 protein…

Feature

Registry could be 'invaluable' for tracking long-term CAR T-cell therapy outcomes

November 21, 2018
The Center for International Blood and Marrow Transplant Research, through an alliance with Novartis, aims to track the long-term outcomes of…